Performance In Initiating Q3 2018-2019

					Initiating Q3 20	10 2015								
Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
17/LO/2058	231907	A PROSPECTIVE, MULTICENTER, NON- BANDOMITED, POST MARKET CLINICAL FOLLOW UP STUDY CONFIRMS ASTET AND PERSONMANCE OF THE COMERX WAVECREST LET ATRIAL APPRINGED OCCUSION SYSTEM IN CURRENT NON-VALVOULA STRAL REPRILLATION WAVECREST PMCF STUDY - CIKI, IPOSS	Yes	07/03/2018	16/10/2017	02/01/2018	08/01/2018	07/12/2017	11/12/2017	Please Select	01/03/2018	J - Other	Initiation recruitment target as it was at this timepoint met	Neither
17/EE/0382	220851	PRedicting Outcomes For Crohn's disease using a molecular biomarker (PROFILE) trial	No		11/12/2017	02/01/2018	19/01/2018	30/01/2018	07/02/2018	Please Select	24/05/2018	E - Staff availability issues	Initiation recruitment target not met. Delays with IRMER and pharmacy department C&C. Eligible participants did not consent	Sponsor
17/EE/0448	226368	Randomised Controlled Trial of Cryo Ablation versus Cardioversion in Persistent Atrial Fibrillation	Yes	08/03/2018	17/08/2017	04/01/2018	19/12/2017	16/11/2017	23/02/2018	Please Select	26/02/2018	J - Other	Initiation recruitment target, as it was, met. 3 patients recruited and randomised by recruitment target date.	Neither
17/EM/0361	234065	A Mudiscenter, Randomized, Double Blind, Placebo-Convolled Study in Subjects With Relegaing Multiple Sciences to Evaluate the Efficacy and Select of Billio33 as an Add On Therapy to Area-Inflammatory Disease-Modifying Therapies	No		28/06/2017	12/01/2018	11/01/2018	05/02/2018	19/02/2018	Please Select	21/03/2018	D - Sponsor Delays	Initiation target not met. Sponsor changed pharmacy relevant information when site were close to opening and pharmacy SOPs had to be rewritten. Unblinded pharmacy SIV was after main SIV.	Sponsor
17/SC/0164	210735	A multi-centre, randomised, controlled trial evaluating the effects of early high- dose cryoprecipitate in adult patients with major trauma haemorrhage requiring, majorhaemorrhage protocol (MHP) activation	Yes	10/05/2018	22/11/2017	01/02/2018	26/05/2017	18/12/2017	19/02/2018	Please Select	16/03/2018		Recruitment Target Not Met. Discussions over protocol pathway.	Please Select
16/NW/0629	211995	The cystic fibrosis (cf) anti-staphylococcus antibiotic prophysias trial (CF START), a randomised registry trial to assets the safety and effictor, of fluctoracidin as a longterm prophylasis agent for infants with CF.	No		09/02/2018	09/02/2018	22/09/2016	26/03/2018	13/03/2018	Please Select	16/04/2018	I - Rare diseases	FPR 30 Day Target was 26/05/2018, not met. Rare patient group, sponsor sent us the HRA pack early. Recruitment target for this study is 1 participant in	Neither
												J - Other	total.	
18/WM/0017	236521	Post-Market Clinical Investigation of the Clarecer [®] IOL	Yes	04/06/2018	09/01/2018	18/05/2018	16/02/2018	16/04/2018	18/04/2018	Please Select	16/12/2018	D - Sponsor Delays	BSUH were the first site in the UK to be open to recruitment. The sponsor wanted the site to open at a specific time point. First patient recruited within 17 days of site activation.	Sponsor
17/SW/0255	234748	Clinical Trial Evaluation of the Percutaneous 4 Tech TriCinch Coil Tricuspild Valve Repair System	No		22/02/2018	22/02/2018	21/02/2018	15/08/2017	06/09/2017	Please Select	18/09/2018	D - Sponsor Delays	Sponsor submitted a substantial amendment during set up. FPR 05October2018	Sponsor
17/NS/0018	223787	Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a evaluate the effectiveness and cost effectiveness inswise urodynamic investigations in management of women with refractory overactive bladder symptoms.	No		05/03/2018	05/03/2018	11/08/2017	27/02/2018	23/04/2018	Please Select		F-No patients seen	Initiation target not met despite screening for study. Media stories have had an impact on participants' willingnesst to participate.	Neither
18/SC/0055	239091	Evaluating the effect of immunisation with group 8 meningococcul vaccines on meningococcul carriage	Yes	24/04/2018	05/02/2018	12/03/2018	05/03/2018	18/04/2018	18/04/2018	Please Select	19/04/2018	F-No patients seen	Initiation target just missed. First patient recruited patient 37 days, no eligible patients seen before this time point.	Neither

				Performance In	mitiating Q3 20	110-2019								
Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
17/LL/2093	228763	A phase IV, open-label pillot study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fathy liver disease randomised to receiving OBT plus maraviroc or OBT	Yes	06/04/2018	24/11/2017	19/03/2018	28/02/2018	19/03/2018	27/03/2018	Please Select	28/03/2018	J - Other	Initiation target met	Neither
16/LO/1905	195890	A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HV coinfection (REACT)	Yes	23/04/2018	07/01/2018	12/04/2018	31/03/2017	28/03/2018	28/03/2018	Please Select	13/04/2018		Initiation target met. Opened to recruitment 13 April 2018. No HRA approval/ assessment documentation was received until 12 April, therefore the site selected date was after the date of site and sponsor confirmed dates.	Please Select
17/NI/0204	230772	Nordic Baltic British Study on Optical Coherence	No		04/12/2017	10/07/2018	05/04/2018	28/06/2018	28/06/2018	Please Select	10/07/2018	D - Sponsor Delays	Initiation target not met. Delays in receiving documents from the sponsor.	Sponsor
18/SC/0155	236211	A multicentre international randomized parallel group double-blind placebo- controlled dirical ratio of EMPA/ellioni once daily to susess cardio-renal outcomes in judient with draviori. NUMEY disease	No		23/04/2018	23/04/2018	26/04/2018	06/07/2018	17/07/2018	Please Select	31/07/2018	J - Other	Initiation target not met. Sponsor and Site had agreed a later start date because training in Oxford was required before screening takes place. Training started on 11/12 December 2018. No patients recruited to date.	Neither
16/NS/0106	212541	Reducing Asthma Attacks in Children using Eshaled Nitric Colde as a biomarker to inform treatment strategy— A randomised trial (RAACENO)	Yes	02/08/2018	09/03/2018	08/05/2018	04/04/2017	17/04/2018	07/05/2018	Please Select	08/05/2018	G - No patients consented	Initiation target wasn't met. 6 patients were approached by that date but none consented by then. 31/12/2018 participants recruited to date, out of 43 screened.	Neither
18/LO/0727	245123	Post-Market Clinical Follow-Up Study to Monitor Device Performance and Outcomes of the CENTERA Heart Valve System	No		04/07/2018	04/07/2018	28/02/2018	04/07/2018	10/09/2018	Please Select	05/10/2018	F - No patients seen	Sponsor wanted the lead site to open up first, so initiation target not met.	Sponsor
18/NW/0228	240364	A Phase 2b, Randomised, Multi-Center, Double Blind, Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intraventur XM-954 in Critically III Patients with Enteral Feeding Intolerance	No		18/05/2018	18/05/2018				Sponsor declined site confirmation			Sponsor declined site confirmation	Please Select
17/10/0731	219463	A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost	Yes	29/06/2018	23/11/2017	19/06/2018	27/07/2017	17/01/2018	18/01/2018	Please Select	19/06/2018	A - Permissions delayed/denied	First patient recruited 29/06/2018, some delays with internal RTQA approvals	NHS Provider
18/NE/0132	242937	A PHASE II, RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ABM STUDY TO EVALUATE THE PHASHACKOMENTS. SUBCUTARNOUS ADMINISTRATION OF THE FREE DOSE COMBINATION OF PETRUZUMABA BOTTASTUZUMAB CHEMOTHERAPY IN PATENTS WITH HEEZ POSITIVE EARLY BREAST CANCER	Yes	09/08/2018	27/02/2018	24/05/2018	07/06/2018	25/05/2018	07/06/2018	Please Select	24/07/2018	F - No patients seen	None	Neither

Performance In Initiating Q3 2018-2019

				Performance In	minuting Q3 E0	10 2015								
Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
17/YH/0228	222492	CALM-2 - CONTROLLING AND LOWERING BLOOD PRESSURE WITH THE MOBIUSHO*	No		15/02/2018	12/06/2018	05/10/2017	03/05/2018	04/05/2018	Please Select	13/06/2018	F - No patients seen	No eligible patients seen so far despite intensive screening and social media recruitment campaigns & screening over 150 patients. Issues with recruitment studywide.	Neither
18/SC/0211	241498	Comparing 2D and 3D photography with computerised analysis for earlier detection of cranifocatic changes of fetal alcohol spectrum disorder in newborn infants with and without prenatal alcohol exposure	Yes	19/06/2018	19/06/2018	19/06/2018	23/05/2018	19/06/2018	19/06/2018	Please Select	19/06/2018	J - Other	Delays with internal training after C&C was given.	NHS Provider
18/EM/0119	244650	A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumah (Mik-3475) in Tki- resistant EGFR-mutated Tumors in Metastatic Non-syamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)	No		19/04/2018	28/06/2018	06/07/2018	03/07/2018	05/07/2018	Please Select	16/08/2018	F - No patients seen	No eligible patients seen, our target is 3 per annum	Neither
18/SW/0130	246372	Prospective Evaluation of Thin-strut Biodegradule Polymer coated Suprafles Stroffmus-Edining Steen is an Allocomes Patient Population (S-FLIX UK-8)	No		02/07/2018	02/07/2018	29/06/2018	25/07/2018	30/07/2018	Please Select	08/08/2018	D - Sponsor Delays	BSUH is the first amongst 30 sites to be ready to recruit for this study but sponsor decided to use a new stent which required CE marking, so initiation target not met.	Sponsor
18/5C/0243	240684	HPS-4/TIMI 65/ORION-4: A double-billed randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atheroschrotic cardiovascular disease	No		24/07/2018	24/07/2018				Please Select	05/12/2018	D - Sponsor Delays	No patients recruited at the reporting time point.	Both
17/LO/0621	191390	STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: A Multi-Centre, Randomized, Controlled Trial	No		18/04/2018	18/04/2018	22/05/2017			Please Select		Jeen	Study was still in set up at the reporting cut off time point	Please Select
17/LO/1711	234276	Synbiotic Extensively Hydrolysed Feed Study	No		04/07/2018	25/07/2018	14/09/2018	25/07/2018	31/07/2018	Please Select	14/09/2018	G - No patients consented	Large numbers of approached participants declining to take part.	Neither
18/EE/0222	233921	A randomized controlled trial of very early versus delayed angiography 4/- intervention on outcomes in patients with non ST-elevation myocardial infarction	Yes	12/12/2018	20/06/2018	27/07/2018	12/09/2018	26/09/2018	01/10/2018	Please Select	03/10/2018	D - Sponsor Delays	Initiation target not met. There was a sponsor delay in organizing the SIV. Also incorrect hospitals details were on IRAS, therefore, a NSA had to be processed.	Sponsor
18/HRA/1559	243467	The influence of social care on delayed transfers of care	No		27/07/2018	27/07/2018	28/02/2018	27/07/2018	27/07/2018	Please Select	03/08/2018	J - Other	First patient recruitment date	NHS Provider
18/LO/0773	214890	transters of care Limiting Undetected Sexually Transmitted Infections to RedUce Morbidity: A qualitative exploratory approach to investigate the Accelerated Partner Therapy intervention in patients and health professionals (LUSTRUM Pre-trial Development Work)	No		20/07/2018	20/07/2018				Site declined to participate		A - Permissions delayed/denied	unknown 05/09/2018 Site declined to participate	Neither

Performance In Initiating Q3 2018-2019

Performance In Initiating Q3 2018-2019														
Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
18/ES/0067	216343	Brain Imaging to predict Toxicity in Elderly patients after Radiotherapy	Yes	05/09/2018	03/07/2018	01/08/2018	28/06/2018	01/08/2018	01/08/2018	Please Select	08/08/2018	J - Other	Initiation target met	Neither
0	247770	To evaluate the acceptability (including gastro intestinal tolerance and compliance) of a low calorie peptide based paedistric tube-feed formula; for children greater than 1 year of age.	Yes	31/10/2018	03/08/2018	03/08/2018	10/07/2018	03/08/2018	03/08/2018	Please Select	03/08/2018	F - No patients seen	Out of 5 participants screened, one was recruited and only became eligible after the initiation target date.	Neither
18/WA/0161	238902	AN OPEN-LABEL, MULTI-CENTRE, RANDOMISCO, SWITCH STUDY TO EVALUATE THE VINCIDOGICAL EFFECAY OVER SWEEDS OF ZORION TREADMY. THE ATTENDED HE STORE THE STORE OF THE ATTENDED HE STORE OVER THE ATTENDED HE STORE OVER THE S	No		08/01/2018	06/08/2018	04/10/2018	13/11/2018	13/11/2018	Please Select	13/11/2018	G - No patients consented	initiation target not met, no participants recruited as at 31/12/2018. Only 36 potential participants out of a cohort of 2300. Strict inclusion exclusion criteria. Pts unwilling to switch stable drug regime. Green light 13/11/2018	Neither
18/NW/0476	246649	Involve-CAT: A Feasibility Randomised Controlled Trial of a Cataract Decision Aid	Yes	09/10/2018	06/08/2018	06/08/2018	06/09/2018	17/09/2018	21/09/2018	Please Select	26/09/2018	A - Permissions delayed/denied	First patient recruited, however 30 day first patient recruitment target was missed as HRA approval was awaited.	Neither
18/LO/0612	235872	CLEAR SYNERGY (DASS 9): A 2x2 factorial randomized controlled trial of couldines and spinonal-control in pasters with 51 elevation myocAPdials infarction.) YMERSY Sterk Registry— Organisation to Autens Soring pie for lockens. Syndromes 9	No		28/05/2018	08/08/2018	16/07/2018	08/08/2018	17/09/2018	Please Select	05/12/2018	D - Sponsor Delays	Sponsor wanted to delay shipping drugs until after the New Year because their distributor had a backlog so it has not been possible to recruit a participant yet.	Sponsor
17\NI\0162	232288	A phase 3 randomised, double blind, clinical trial investigating the effectiveness of repurposed sinvastatin compared to placebo, in secondary progressive multiple sclerosis, in slowing the progression of disability	Yes	23/10/2018	13/06/2018	18/09/2018	19/01/2018	12/07/2018	24/07/2018	Please Select	18/09/2018	E - Staff availability issues	Initiation target not met due to staffing issues at site.	NHS Provider
18/L0/0995	244737	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lanvalities in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with Advanced Endometrial Cancer	No		05/06/2018	21/09/2018	20/09/2018	28/08/2018	20/09/2018	Please Select	14/11/2018	A - Permissions delayed/denied F - No patients seen	Initiation Target Not Met. Delays in confirming capacity and capability and no eligible patients seen at the reporting cut off point.	NHS Provider
18/LO/0864	245423	Safety & efficacy of Venetodax + Fulvestrant in ER+MBC patients	No		03/07/2018	03/07/2018	19/09/2018	30/08/2018	04/09/2018	Please Select	07/12/2018	J - Other	Aim to recruit by 06th January 2019. Delays with ARSAC approvals due to national change in licence system. First patient consende 31/12/2018 but not yet fully on study	Neither
15/WM/0443	188505	PDCOMM A multicentre randomised controlled trial to compare the clinical and cost effectiveness of the Silveness of the Silve	No		22/06/2018	12/10/2018	20/06/2016	01/08/2018	28/08/2018	Please Select	18/10/2018	G - No patients consented	Initiation Target Not Met. Participants did not wish to consent due to the travel involved.	Neither
18/EE/0234	248832	Surveillance of arteriovenous fistulae using ultrasound (SONAR) v1.0	No		04/10/2018	12/12/2018	07/08/2018	12/12/2018	12/12/2018	Please Select	28/12/2018		Still within the initiation recruitment window at the reporting cut off point	Please Select
17/LO/2041	234256	Chronic Hypertenion in pregnAncy iMPlementatiON study (CHAMPION)	Yes	01/08/2018	05/06/2018	09/07/2018	11/01/2018	09/07/2018	09/07/2018	Please Select	09/07/2018		Initiation target met	Please Select
18/YH/0417	247000	Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BilB078 Administered Intrathecally to Adults with C9ORF72-Associated Amyotrophic Lateral Sclerosis	No		29/11/2018	29/11/2018				Please Select			Study still in set up at reporting cut off timepoint	Please Select